for Radiotherapy Planning

Sep 1, 2016 by in NUCLEAR MEDICINE Comments Off on for Radiotherapy Planning

Fig. 1 ICRU target volumes The second important tool for the planning of percutaneous irradiations are DVHs. Here, the dose given to a certain structure like a target volume or a…

read more

Radionuclide Therapy of Prostate Cancer

Sep 1, 2016 by in NUCLEAR MEDICINE Comments Off on Radionuclide Therapy of Prostate Cancer

Fig. 1 Schematic diagram of prostate carcinoma cell depicting transmembrane prostate specific membrane antigen (PSMA). The extracellular portion binds antibody J591 which has been used labeled with Lutetium-177 and other radionuclides…

read more

Radioimmunotherapy in Conditioning of Acute Leukemia, MDS, and Multiple Myeloma Prior to Hematological Stem Cell Transplantation

Sep 1, 2016 by in NUCLEAR MEDICINE Comments Off on Radioimmunotherapy in Conditioning of Acute Leukemia, MDS, and Multiple Myeloma Prior to Hematological Stem Cell Transplantation

Myeloablative radioimmunotherapy Aim of therapy Reduction of tumor cell number Conditioning prior to SCT by: Reduction of tumor cell number Myeloablation Antibody specification Tumor cell affinity Bone marrow affinity (Tumor…

read more

Therapy of Hyperthyroidism (Toxic Goiter, Hyperfunctioning Nodule) and Non-Toxic Goiter: Procedures and Guidelines

Sep 1, 2016 by in NUCLEAR MEDICINE Comments Off on Therapy of Hyperthyroidism (Toxic Goiter, Hyperfunctioning Nodule) and Non-Toxic Goiter: Procedures and Guidelines

  Antithyroid drug Surgery Radioiodine Time to initial improvement 2–4 weeks Needs antithyroid drug pretreatment (toxic goiters) Needs antithyroid drug pretreatment; 4–8 weeks after RIT Recurrence 90–100 % (toxic goiters) 1–4 %…

read more
Get Clinical Tree app for offline access